- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02032303
Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
Study design Investigators aim to perform a prospective, single-center, investigator-initiated, randomized study to compare the Adenosine-induced coronary vasodilatation after the loading dose of Ticagrelor either Prasugrel during the Percutaneous Coronary Intervention. Patients with acute coronary syndrome undergoing Percutaneous Coronary Intervention will be enrolled in the study and will be randomized, in a 1:1 ratio, to receive a loading dose of Ticagrelor (180 mg) or Prasugrel (60 mg). In patients with non-ST elevation myocardial infarction these drugs will be administered only when the coronary anatomy will be known, to avoid bleeding due to prasugrel, in patients suitable for coronary artery bypass grafting as recommended by European Society of Cardiology guidelines (Class IB) (10). In patients with ST elevation myocardial infarction, instead, prasugrel and ticagrelor will be administrated before the procedure, according to the European Society of Cardiology guidelines (Class IB) (11). Coronary Flow Reserve will be recorded by intracoronary Doppler Flow Wire before the stent implantation and after the procedure at baseline and 2-minute later adenosine intravenous administration at incremental doses of 50, 80, 110 and 140 ug/Kg/min with 2 minutes interval between infusions.
Coronary Flow Reserve is the ability of the myocardium to increase blood flow in response to maximal exercise. Doppler Flow Wire allows to measure this increase expressing it as a ratio between maximal vasodilation and flow at rest. Coronary Flow Reserve is routinely measured in patients with acute coronary syndrome, without an increased risk of adverse events for patients neither adjunctive costs for the National Health System.
Furthermore, Plasma concentrations of Ticagrelor and its main metabolite (AR-C124910XX) will be measured in venous blood collected at the end of the procedure. . In patients requiring a second Percutaneous Coronary Intervention, for example for multivessel disease, all these measures will be repeated in the same manner.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Rome, Italien, 00100
- Massimo Mancone
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
• Patients with acute coronary syndrome undergoing Percutaneous Coronary Intervention with stent implantation;
- Patients ≥ 18 and ≤ 75 years old.
- Signed informed consent;
Exclusion Criteria:
• Patients with stable angina;
- prior myocardial infarction;
- prior revascularization (Percutaneous Coronary Intervention or coronary artery bypass grafting);
- Ticagrelor contraindications (history of intracranial hemorrhage, active pathological bleeding, severe hepatic impairment);
- Prasugrel contraindications (patients weighing less than 60 kg, patients who had previous stroke or transient ischemic attack, patients aged more than 75 years old);
- major periprocedural complications;
- suboptimal Percutaneous Coronary Intervention result (residual stenosis > 20%);
- glomerular filtration rate < 30 ml/min or requiring haemodialysis;
- Non-sinus rhythm;
- severe chronic obstructive pulmonary disease;
- requirement for oral anticoagulant;
- risk of bleeding or bradycardic events;
- ejection fraction < 45%;
- Cardiogenic shock;
- Severe left ventricular hypertrophy;
- severe valvular disease;
- diffuse coronary atherosclerosis;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Ticagrelor
Patient randomized to Ticagrelor
|
|
|
Aktiv komparator: Prasugrel
Patient randomized to Prasugrel
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
assessment of coronary flow reserve
Tidsramme: 2 hours after the loading dose
|
2 hours after the loading dose
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Iskæmi
- Patologiske processer
- Nekrose
- Myokardieiskæmi
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Smerte
- Neurologiske manifestationer
- Sygdom
- Brystsmerter
- Hjertekrampe
- Myokardieinfarkt
- Infarkt
- Syndrom
- ST Elevation Myokardieinfarkt
- Akut koronarsyndrom
- Angina, ustabil
- Ikke-ST forhøjet myokardieinfarkt
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Blodpladeaggregationshæmmere
- Purinerge P2Y-receptorantagonister
- Purinerge P2-receptorantagonister
- Purinerge antagonister
- Purinerge midler
- Ticagrelor
- Prasugrel Hydrochlorid
Andre undersøgelses-id-numre
- Ticagrelor - Prasugrel
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ST Elevation Myokardieinfarkt
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergAfsluttetMyokardieinfarkt | ST-elevation myokardieinfarkt | Ikke-ST-elevation myokardieinfarktTyskland
-
University Medical Centre LjubljanaAfsluttetHjertestop | Postresuscitation syndrom | Myokardieinfarkt (ST-elevation myokardieinfarkt og ikke-ST-elevation myokardieinfarkt)Slovenien
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUkendtAkut koronarsyndrom | STEMI | NSTEMI - Ikke-ST Segment Elevation MI | Ikke ST-segment elevation myokardieinfarkt | Ikke-ST Elevation myokardieinfarkt | STEMI - ST Elevation myokardieinfarkt | Akut koronararterietrombose (diagnose) | Ikke ST-segment elevation Akut koronarsyndrom | Ikke-ST Elevation Myokardieinfarkt... og andre forholdForenede Stater
-
University of LeedsUniversity College, LondonAfsluttetST-elevation Myokardieinfarkt | Myokardieinfarkt uden ST-elevation
-
Azienda ULSS 5 PolesanaUniversity of PadovaUkendtMyokardieinfarkt, akut | ST Segment Elevation Myokardieinfarkt | Ikke-ST Elevation Myokardieinfarkt (nSTEMI)Italien
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationAfsluttetST Elevation Myokardieinfarkt | Ikke ST Elevation myokardieinfarktForenede Stater, Spanien, Holland, Canada, Australien, Serbien, Egypten, Schweiz, Ungarn, Det Forenede Kongerige, Frankrig, Tjekkiet, Nepal, Nordmakedonien
-
University Hospital, Basel, SwitzerlandUniversity of BaselRekrutteringNSTEMI - Ikke-ST Segment Elevation MI | ST-segment elevation myokardieinfarkt (STEMI) | Akut kardiovaskulær sygdomSchweiz
-
Inha University HospitalAfsluttetST Segment Elevation Myokardieinfarkt | Ikke-ST-segment elevation myokardieinfarktKorea, Republikken
-
Chinese PLA General HospitalAfsluttetST Elevation (STEMI) MyokardieinfarktKina
-
RenJi HospitalAfsluttetST Segment Elevation Myokardieinfarkt
Kliniske forsøg med Perkutan koronar intervention
-
Second Affiliated Hospital, School of Medicine,...Zhejiang University; First Affiliated Hospital of Wenzhou Medical University og andre samarbejdspartnereLedigST Elevation MyokardieinfarktKina
-
The University of Texas Health Science Center,...AfsluttetMyokardieinfarkt | Hjerte sygdom | Akut myokardieinfarktForenede Stater
-
Shenzhen Core Medical Technology CO.,LTD.Rekruttering
-
Shenzhen Core Medical Technology CO.,LTD.Rekruttering
-
London North West Healthcare NHS TrustAfsluttetFistel i AnoDet Forenede Kongerige
-
Pulse Biosciences, Inc.AfsluttetSkjoldbruskkirtel nodule (godartet)Italien
-
ViacorAfsluttetHjertefejl | Mitral regurgitationCanada
-
Mitralign, Inc.CardioVascular Research Foundation, Korea; Regulatory and Clinical Research... og andre samarbejdspartnereUkendtSikkerhed og ydeevne af Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) (SCOUT-II)Hjerteklapsygdom | Trikuspidalventilinsufficiens | Kronisk symptomatisk funktionel trikuspidal regurgitationItalien, Holland, Tyskland, Portugal
-
Medtronic Spinal and BiologicsAfsluttetSpinal stenoseTyskland, Belgien, Det Forenede Kongerige
-
ViacorDuke University; Medifacts International CorporationSuspenderetHjertefejl | Mitral regurgitationBelgien, Tjekkiet, Tyskland, Holland, Schweiz